Table 1.
Characteristic of patients with Behçet’s disease who were enrolled in the study
| Characteristics | Yokohama City University registry (n = 657) | Japan national registry (n = 6754) |
|---|---|---|
| Sex: female/male, n (%) | 372/285 (56.6/43.4) | 3990/2764 (59.1/40.9) |
| Age of diagnosis (mean ± SD) | 36.58 ± 12.29 | 36.68 ± 14.23 |
| Observation period (mean ± SD) | 13.72 ± 11.79 | 4.14 ± 7.62 |
| Disease phenotype | ||
| Oral ulcer, n (%) | 653 (99.4) | 6336 (93.8) |
| Skin involvement, n (%) | 585 (89.0) | 5483 (81.2) |
| Eye involvement, n (%) | 392 (59.7) | 2344 (34.7) |
| Genital ulcer, n (%) | 474 (72.1) | 4242 (62.8) |
| Arthritis, n (%) | 346 (52.7) | 3311 (49.0) |
| Epididymitis, n/available data number (%) | 15/285 (5.3) | 257/2764 (9.3) |
| Gastrointestinal involvement, n (%) | 113 (17.2) | 906 (13.4) |
| Vascular involvement, n (%) | 55 (8.4) | 148 (2.2) |
| Neurological involvement, n (%) | 67 (10.2) | 350 (5.2) |
| Pathergy test, n/available data number (%) | 74/170 (43.5) | 1361/4225 (32.2) |
| Other characteristics | ||
| HLA-B51, n/available data number (%) | 214/449 (47.7) | 1389/3141 (44.2) |
| Fulfilling ISG criteria, n (%) | 583 (88.7) | 4980 (73.7) |
| Fulfilling ITR-ICBD criteria, n (%) | 645 (98.2) | 5586 (82.7) |
| Smoking, n/available data number (%) | 233/455 (51.2) | N/A |
| Hospitalization, n/available data number (%) | 239/522 (45.8) | 1556/6002 (25.9) |
| Blindness, n/available data number (%) | 98/582 (16.8) | N/A |
| Death caused by BD, n/available data number (%) | 3/520 (0.6) | N/A |
| Treatments | ||
| Colchicine, n (%) | 375/522 (71.8) | 2942 (43.6) |
| Glucocorticoid, n (%) | 236/522 (45.2) | 2352 (34.8) |
| Maximum Prednisolone dose (mg/day, mean ± SD) | 11.75 ± 17.76 | N/A |
| Methylprednisolone pulse therapy, n/available data number (%) | 36/522 (6.9) | N/A |
| Immunosuppressant therapy, n/available data number (%) | 203/522 (38.9) | 578 (8.6) |
| Biologics, n (%) | 95 (14.5) | N/A |
| Infliximab, n (%) | 86 (13.1) | N/A |
| Adalimumab, n (%) | 24 (3.7) | N/A |
| Others, n (%)* | 3 (0.5) | N/A |
| Time from diagnosis to biologics (years, mean ± SD) | 6.22 ± 8.52 | N/A |
BDRC Behçet’s Disease Research Committee, ISG International Study Group, ITR-ICBD International Team for the Revision of the International Criteria for Behçet’s Disease, N/A not available
*Others: etanercept 2, tocilizumab 1